Institute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100050, China.
Molecules. 2022 Jun 10;27(12):3738. doi: 10.3390/molecules27123738.
As a global health problem, liver fibrosis still does not have approved treatment. It was proved that -(3,4,5-trichlorophenyl)-2(3-nitrobenzenesulfonamide) benzamide (IMB16-4) has anti-hepatic fibrosis activity. However, IMB16-4 displays poor water solubility and poor bioavailability. We are devoted to developing biodegraded liposome-coated polymeric nanoparticles (LNPs) as IMB16-4 delivery systems for improving aqueous solubility, cellular uptake, and anti-fibrotic effects. The physical states of IMB16-4-LNPs were analyzed using a transmission electron microscope (TEM), high-performance liquid chromatography (HPLC), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD) and differential scanning calorimeter (DSC). The results show that IMB16-4-LNPs increased the drug loading compared to liposomes and enhanced cellular uptake behavior compared with IMB16-4-NPs. In addition, IMB16-4-LNPs could repress the expression of hepatic fibrogenesis-associated proteins, indicating that IMB16-4-LNPs exhibited evident anti-fibrotic effects.
作为一个全球性的健康问题,肝纤维化仍然没有被批准的治疗方法。研究证明,(3,4,5-三氯苯基)-2(3-硝基苯磺酰胺)苯甲酰胺(IMB16-4)具有抗肝纤维化活性。然而,IMB16-4 的水溶性差,生物利用度低。我们致力于开发可生物降解的脂质体包覆的聚合物纳米粒(LNPs)作为 IMB16-4 递药系统,以提高其水溶解度、细胞摄取率和抗纤维化效果。使用透射电子显微镜(TEM)、高效液相色谱(HPLC)、傅里叶变换红外光谱(FTIR)、X 射线衍射(XRD)和差示扫描量热法(DSC)分析了 IMB16-4-LNPs 的物理状态。结果表明,与脂质体相比,IMB16-4-LNPs 增加了药物载药量,与 IMB16-4-NPs 相比,增强了细胞摄取行为。此外,IMB16-4-LNPs 可以抑制肝纤维化相关蛋白的表达,表明 IMB16-4-LNPs 具有明显的抗纤维化作用。